Marinomed Biotech Ag · VIE:MARI
Marinomed Biotech — Equity Forum – German Spring Conference 2022
27 slides from Marinomed Biotech's conference presentation, May 23, 2022
Slide 1: Investor Presentation
Investor Presentation Equity Forum – German Spring Conference 2022 23rd May 2022
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) was prepared by Marinomed Biotech AG. The information contained in this Presentation has not been independently verified and no representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy
Slide 3: Marinomed investment highlights
Marinomed investment highlights Transforming lives of people living with diseases with limited or no treatment options • Management team with 100+ years of experience in biopharma with track record spanning from invention to commercialization • Short term growth perspective with existing product por
Slide 4: Marinomed management and ownership
Marinomed management and ownership Total number of shares 13.7% 1,496,287 Left to right: 8.4% Pascal Schmidt, CFO; Eva Prieschl-Grassauer, CSO and co-founder; Cornelia Kutzer, CBO, Acropora Beteiligungs GmbH Andreas Grassauer, CEO and co-founder 8.1% Dr. Hermann Unger 61.7% DI Dr. Andreas Grassauer
Slide 5: Marinomed at a glance
Marinomed at a glance Unmet medical need Lean, public company with track record of Company Focus on rare diseases such as herpetic stromal successfully inventing, keratitis, the leading cause of Founded partnering and in 2006 infectious blindness in developed countries1 marketing products First prod
Slide 6: Strategic horizons for Marinomed
Strategic horizons for Marinomed Long-term vision Strategy 2025f Leading biopharma company for rare autoreactive immune disorders and Move towards higher valued viral infectious diseases Rx drugs addressing unmet Short-term medical needs Maximise current OTC portfolio Succeed with next-generation
Slide 7: Marinomed has built a proven track record
Marinomed has built a proven track record Successes in the therapeutic areas Immunology Virology • First aqueous steroid solution, all other major • Discovery of the viral efficacy of Carragelose against competitors are suspensions respiratory viruses • Performance of a series of clinical studies to
Slide 8: Strategy 2025
Strategy 2025 Creating sustainable value for patients and shareholders High relevance High attractiveness High chance of partnering © Marinomed Biotech AG 8
Slide 9: Strong pipeline – still more to come
Strong pipeline – still more to come Growth potential to pursue Solid base to build on © Marinomed Biotech AG 9
Slide 10: Fighting against visual impact
Fighting against visual impact Rare disease herpetic stromal keratitis caused by ocular herpes virus infection Prevalence Unmet medical need Herpesvirus induced keratitis • >90% of the global population has a latent In the developed world without China infection with HSV-1 by the age of sixty1 Epith
Slide 11: Tacrolimus
Tacrolimus Best in class macrolide immunosuppressant –a substance that could benefit so many more patients when solubilized • Macrolide calcineurin inhibitor Tacrosolv is a Marinosolv-enabled formulation of Tacrolimus in an aqueous solution1 • Practically insoluble in water Bioavailability is strong
Slide 12: Tacrosolv
Tacrosolv Fully solubilized macrolide immunosuppressant – validated in clinical phase II trial TOSS* day 8 % reduction compared to day 1 Rationale for the use of Tacrosolv 6 • Clinical proof of concept in the model Placebo Verum 5 0 indication allergic conjunctivitis showing an anti-inflammatory act
Slide 13: Autoimmune gastritis
Autoimmune gastritis Chronic inflammatory disorder of stomach lining without specific treatment available What is AIG? Standard of care Prevalence • Inflammation of gastric mucosa due to • No effective anti-inflammatory • Highly variable due to different use of an autoimmune reaction treatment avail
Slide 14: INHALeeN – inhalable broad-spectrum antiviral
INHALeeN – inhalable broad-spectrum antiviral Addressing the global need for improved treatment options for respiratory infections across virus families infectious viral pathogen in Evolving viral strains due to Pandemic Endemic constant mutations1 hospitalized patients2 2,10% 8,10% 20,20% 8,20% Glo
Slide 15: INHALeeN
INHALeeN Broad-spectrum inhalable combination antiviral designed to optimally treat respiratory infections caused by major pathogenic viral families Rationale for the use of iota- Virus-blocking Efficacy of the combination of IC and carrageenan (IC) Virus type activity zanamivir against influenza H7
Slide 16: Business model
Business model Lean structure focused on creating sustainable values Collaborations with Research Revenue from and • Upfront • Academia Partnering • Milestones • Innovative partners invention • Royalties • KOLs Generation of IP Partly outsourcing to Pre- • CROs clinical Early • Planning of clinical
Slide 17: Market potential
Market potential Marinomed tapping into high value markets Immunology – Tacrosolv HSK target population in thousand Virology – INHALeeN population at-risk in million people2 people1 80 400 60 300 40 200 20 100 0 0 United States Europe 5 Japan China United States Europe 5 Japan China Increased risk H
Slide 18: Sustainability
Sustainability Marinomed contributes to sustainability goals and adheres to ESG • Develop products containing less API – for patients and for the environment • Use more renewable energy • Promote environmentally friendly supply chains ENVIRONMENT • Therapies for people living with diseases with limi
Slide 19: Financial performance
Financial performance Solid business as basis for future growth Historical performance (revenues and EBIT) Key growth drivers 11.6* Virology 8.1 4.7 6.1 Carragelose business Revenues • Established in >40 countries with strong distribution and marketing partners EBIT • Strong revenue generation, EBIT
Slide 20: Timeline 2022/2023
Timeline 2022/2023 News flow / milestones • January – Strengthening business development through new CBO Cornelia Kutzer • February – Draw down of €6m EIB financing tranche News flow to • April – New agreement with Hanmi for marketing of Carragelose in South Korea date • April – Publication of stron
Slide 21: The Marinomed story
The Marinomed story Transforming lives of people living with diseases with limited or no treatment options • Highly experienced management • Short term and long-term growth perspective • Therapies for diseases with unmet medical need • Lean and efficient business model • Sustainable therapies © Mari
Slide 22: Appendix
Appendix © Marinomed Biotech AG 22
Slide 23: Carragelose
Carragelose Expertise in Virology – brought to market Mode of action Partner Logos (sample) Carragelose covers the viral surface unspecifically Product pictures (sample) Prophylactic and therapeutic efficacy clinically validated Baltics Broadly active across several respiratory virus Nordics familie
Slide 24: INHALeeN – inhalable broad-spectrum antiviral
INHALeeN – inhalable broad-spectrum antiviral Antivirals & monoclonal antibodies are still falling short of being universally usable Monoclonal Antivirals: e.g. Iota- Desired state antibodies Paxlovid carrageenan Broad coverage across virus families - - XXX No susceptibility to resistance - X XXX Co
Slide 25: Fighting against visual impact
Fighting against visual impact Rare disease herpetic stromal keratitis caused by ocular herpes virus infection >90% of the global population has a 1.7M cases of herpetic stromal Stromal HSK is a rare disease affecting about latent infection with HSV-1 by the keratitis (HSK) due to Herpes virus 400.0
Slide 26: Autoimmune gastritis
Autoimmune gastritis Chronic inflammatory disorder of stomach lining without specific treatment available What is AIG? Standard of care Prevalence • Diffuse symptoms incl. dyspepsia, bloating, diarrhoea, pain • No effective anti-inflammatory • Highly variable due to different use of • Iron and Vit B
Slide 27: Autoimmune gastritis
Autoimmune gastritis Chronic inflammatory disorder of stomach lining without specific treatment available What is AIG? Standard of care Prevalence • Inflammation of gastric mucosa due to • No effective anti-inflammatory • Highly variable due to different use of an autoimmune reaction treatment avail
Marinomed Biotech — Equity Forum – German Spring Conference 2022 on 6ix